Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-217 nanoparticle
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins University
- Modality
- Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
miR-217 nanoparticle is an experimental RNA-based therapeutic being developed for the treatment of glioblastoma multiforme (GBM). It utilizes a nanoparticle delivery system to restore levels of microRNA-217 (miR-217), a tumor-suppressive miRNA that is frequently downregulated in GBM. miR-217 acts by directly targeting and inhibiting the expression of EZH2 (Enhancer of zeste homolog 2), the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2). In GBM, EZH2-mediated H3K27 trimethylation maintains a cancer stem cell phenotype and represses tumor suppressor genes. By inhibiting EZH2, miR-217 nanoparticles re-activate these tumor suppressors, inhibit tumor growth, and enhance the efficacy of ionizing radiation.
- Other names
- microRNA-217 nanoparticlemicroRNA217 nanoparticlemicroRNA 217 nanoparticle
02
Targets
EZH2 (Histone-lysine N-methyltransferase EZH2)
Beyond the preview
Go deeper on miR-217 nanoparticle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-217 nanoparticle.